《妊娠期HBV的阻断、预防、治疗和随访管理》解读

申姣春; 冷雪君; 张莹; 颜学兵

doi:10.3969/j.issn.1001-5256.2016.06.008

《妊娠期HBV的阻断、预防、治疗和随访管理》解读

DOI: 10.3969/j.issn.1001-5256.2016.06.008

徐州医学院附属医院感染性疾病科

基金项目:

国家自然科学基金(81371867)；江苏省医学科技专项-新型临床诊疗技术攻关(BL2014033)；江苏省“科教兴卫”医学重点人才培养基金(RC2011117)；江苏省“六大人才高峰”项目(2011-WS-068)；

详细信息

中图分类号: R714.251
计量
- 文章访问数: 2786
- HTML全文浏览量: 7
- PDF下载量: 660
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Research funding:

摘要

摘要: <正>慢性乙型肝炎（CHB）是全球公众健康的首要危险因素,并且是潜在疾病进展为肝硬化和肝细胞癌的主要病因。大部分HBV感染者主要由母婴传播（mother-to-child transmission,MTCT）导致。由于通过MTCT感染者大多数会转变为慢性HBV感染,在妊娠期给予适当的预防和管理对于预防MTCT至关重要,所以预防HBV围产期传播是全球努力减少慢性HBV感染负担的重要组成部分。
- 肝炎病毒,乙型 /
- 疾病传播,垂直 /
- 治疗
- hepatitis B virus /
- disease transmission /
- vertical

HTML全文

参考文献(41)

[1]Committee of experts on antiviral therapy for special patients with chronic hepatitis B.Expert consensus on antiviral therapy for special patients with chronic hepatitis B:an update in 2015[J].J Clin Hepatol,2015,31(8):1185-1192.(in Chinese)慢性乙型肝炎特殊患者抗病毒治疗专家委员会.慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新[J].临床肝胆病杂志,2015,31(8):1185-1192.

[2]Committee for the management of hepatitis B virus infection in pregnancy.Expert consensus on the management of hepatitis B virus infection in pregnancy[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(1):104-107.(in Chinese)乙型肝炎病毒感染女性生育管理委员会.乙型肝炎病毒感染女性生育管理专家共识[J/CD].中华实验和临床感染病杂志:电子版,2014,8(1):104-107.

[3]Obstetrics Subgroup,Chinese Society of Obstetrics and Gynecology,Chinese Medical Association.Clinical guidelines for the prevention of mother-to-child transmission of hepatitis B virus[J].Chin J Obstetr Gynecol,2013,48(2):151-154.(in Chinese)中华医学会妇产科学分会产科学组.乙型肝炎病毒母婴传播预防临床指南(第1版)[J].中华妇产科杂志,2013,48(2):151-154.

[4] VISVANATHAN K,DUSHEIKO G,GILES M,et al.Managing HBV in pregnancy.Prevention,prophylaxis,treatment and follow-up:position paper produced by Australian,UK and New Zealand key opinion leaders[J].Gut,2016,65(2):340-350.

[5]YANG YB,LI XM,SHI ZJ,et al.Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection:a case report[J].World J Gastroenterol,2004,10(15):2305-2306.

[6]SAFIR A,LEVY A,SIKULER E,et al.Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome[J].Liver Int,2010,30(5):765-770.

[7]TSE KY,HO LF,LAO T.The impact of maternal HBs Ag carrier status on pregnancy outcomes:a case-control study[J].J Hepatol,2005,43(5):771-775.

[8] VIGANA,MORA S,GIACOMET V,et al.In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers[J].Antivir Ther,2011,16(8):1259-1266.

[9] GIBB DM,KIZITO H,RUSSELL EC,et al.Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial[J].PLo S Med,2012,9(5):e1001217.

[10]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[11] LEE SD,LO KJ,TSAI YT,et al.Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus[J].Lancet,1988,2(8615):833-834.

[12]PAN CQ,ZOU HB,CHEN Y,et al.Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J].Clin Gastroenterol Hepatol,2013,11(10):1349-1355.

[13]WANG J,ZHU Q,ZHANG X.Effect of delivery mode on maternalinfant transmission of hepatitis B virus by immunoprophylaxis[J].Chin Med J(Engl),2002,115(10):1510-1512.

[14]SUN DF,CHEN WQ.Analysis of correlation factors of intrauterine interruption failure for HBV infected pregnant women using HBIGduring the last trimester of pregnancy[J].Matern Child Health Care China,2010,25(14):1923-1925.(in Chinese)孙待飞,陈卫群.孕晚期HBIG阻断HBV宫内感染失败的相关因素研究[J].中国妇幼保健,2010,25(14):1923-1925.

[15]YI W,PAN CQ,HAO J,et al.Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers[J].J Hepatol,2014,60(3):523-529.

[16]HUI L,THE S,Mc CARTHY EA,et al.Emerging issues in invasive prenatal diagnosis:safety and competency in the post-NIPT era[J].Aust N Z J Obstet Gynaecol,2015,55(6):541-546.

[17] DAVIES G,WILSON RD,DESILETS V,et al.Amniocentesis and women with hepatitis B,hepatitis C,or human immunodeficiency virus[J].J Obstet Gynaecol Can,2003,25(2):145-148,149-152.

[18]GILES ML,GRACE R,TAI A,et al.Prevention of mother-tochild transmission of hepatitis B virus(HBV)during pregnancy and the puerperium:current standards of care[J].Aust N Z J Obstet Gynaecol,2013,53(3):231-235.

[19] SHI Z,YANG Y,MA L,et al.Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus:a systematic review and meta-analysis[J].Obstet Gynecol,2010,116(1):147-159.

[20]HAN L,ZHANG HW,XIE JX,et al.A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J].World J Gastroenterol,2011,17(38):4321-433.

[21]HAN GR,CAO MK,ZHAO W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].JHepatol,2011,55(6):1215-1221.

[22] JIANG Q,YU M.A retrospective study of the comparisons between telbivudine and lamvudine on the efficacy and safety in antiviral treatment of hepatitis b virus during pregnancy[R].47th Annual Meeting of the European Association for the Study of the Liver,18-22 April 2012.JHepatol,2012,56:s205.

[23]PAN CQ,HAN GR,JIANG HX,et al.Telbivudine prevents vertical transmission from HBe Ag-positive women with chronic hepatitis B[J].Clin Gastroenterol Hepatol,2012,10(5):520-526.

[24]GREENUP AJ,TAN PK,NGUYEN V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J].J Hepatol,2014,61(3):502-507.

[25] CHEN HL,LEE CN,CHANG CH,et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J].Hepatology,2015,62(2):375-386.

[26] SINGH AE,PLITT SS,OSIOWY C,et al.Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants[J].J Viral Hepat,2011,18(7):468-473.

[27]ZHANG SL,YUE YF,BAI GQ,et al.Mechanism of intrauterine infection of hepatitis B virus[J].World J Gastroenterol,2004,10(3):437-438.

[28]SU GG,PAN KH,ZHAO NF,et al.Efficacy and safety of lamivudine treatment forchronic hepatitis B in pregnancy[J].World JGastroenterol,2004,10(6):910-912.

[29]LI XM,YANG YB,HOU HY,et al.Interruption of HBV intrauterine transmission:a clinical study[J].World J Gastroenterol,2003,9(7):1501-1503.

[30] XU WM,CUI YT,WANG L,et al.Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection:a multicentre,randomized,double-blind,placebo-controlled study[J].J Viral Hepat,2009,16(2):94-103.

[31]van ZONNEVELD M,van NUNEN AB,NIESTERS HG,et al.Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection[J].J Viral Hepat,2003,10(4):294-297.

[32]van NUNEN AB,de MAN RA,HEIJTINK RA,et al.Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients[J].J Hepatol,2000,32(6):1040-1041.

[33] HAN GR,JIANG H,ZHAO W,et al.Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission(VT)of chronic hepatitis B(CHB)in highly viremic mothers[R].62nd Annual Meeting of the American Association for the Study of Liver Diseases,4-8 November 2011,San Francisco,USA;Oral 236.Hepatology,2011,54:122a.

[34]NGUYEN V,TAN PK,GREENUP AJ,et al.Anti-viral therapy for prevention of perinatal HBV transmission:extending therapy beyond birth does not protect against post-partum flare[J].Aliment Pharmacol Ther,2014,39(10):1225-1234.

[35]Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[36]GILES M,VISVANATHAN K,LEWIN S,et al.Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J].Gut,2015,64(11):1810-1815.

[37] MOODLEY J,MOODLEY D,PILLAY K,et al.Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring[J].J Infect Dis,1998,178(5):1327-1333.

[38] SHAPIRO RL,HOLLAND DT,CAPPARELLI E,et al.Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment[J].J Infect Dis,2005,192(5):720-727.

[39] BENABOUD S,PRUVOST A,COFFIE PA,et al.Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan,Cote d'Ivoire,in the ANRS 12109 TEm AAStudy,Step 2[J].Antimicrob Agents Chemother,2011,55(3):1315-1317.

[40] SIBERRY GK,JACOBSON DL,KALKWARF HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy[J].Clin Infect Dis,2015,61(6):996-1003.

[41] BORTOLOTTI F,GUIDO M,BARTOLACCI S,et al.Chronic hepatitis B in children after e antigen seroclearance:final report of a 29-year longitudinal study[J].Hepatology,2006,43(3):556-562.

施引文献

资源附件(0)

访问统计